Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts Takeda's MAA for ixazomib

Aug. 21, 2015

MAA validated for emtricitabine/rilpivirine/tenofovir combination tablet

Aug. 21, 2015

EMA to review MAA for palbociclib plus endocrine therapy for HR+/HER2- metastatic breast cancer

Aug. 21, 2015

Gamida Cell reaches agreements on phase III trial design for NiCord

Aug. 12, 2015

ProMetic Life Sciences completes first plasminogen dosing round in phase I trial

Aug. 11, 2015

Dicerna's DCR-PH1 receives orphan drug designation from the EMA

Aug. 7, 2015

EMA accepts filing of MAA for reslizumab

July 29, 2015

EMA committee hands down positive opinion for Zerbaxa

July 28, 2015

Obizur recommended for approval in Europe for acquired hemophilia A

July 28, 2015

EMA committee recommends approval of Cresemba for invasive aspergillosis and mucormycosis

July 28, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 25, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...